Current standard of care combines cytogenetic results with testing for mutations in FLT3, NPM1, CEBPA, and KIT. The presence of FLT3 ITD, NPM1, or CEBPA mutations refines the prognosis of patient with AML with normal karyotype which is normally intermediate risk. This evidence concerns the gene NPM1 and acute myeloid leukemia.